Schizophrenia with negative symptoms implies cognitive deficit, correlated with the hypo frontal phenomena characterized by hypodopaminergism.

The increase of firing through hypoGABA-ergism leads to a glutamate activity exacerbation, emphasizing the cognitive deficit.

The neurotrophic factors increase the regulated release of dopamine/serotonine/GABA neurotransmitters, regulate the synaptic glutamate transmission on the NMDA receptors path and play a role in the protection of the dopaminergic neurons and in maintaining the number of receptors and their functionality .

A clinic observation study included twenty patients with schizophrenia with negative symptoms and cognitive deficit.

Between 2004-2007 a number of 10 patients from this group received second generation antipsychotic and neurotrophic factor (Cerebrolysin), while the other 10 received only antipsychotic drug.

The effects on cognition, global function, as well as daily activities were evaluated at 6, 12 and 18 months.

In the comparative tests on the two groups, the frequency of the individual responses was 30% in the group with associated neurotrophic factor, compared to 10% in the other.

Regarding the definite response for the above mentioned 3 criteria, the frequency of the responses was 10% in the group with associated neurotrophic factor, compared to 5% in the other.

The neurotrophic factor significantly reduces the cognitive decline in: global response, functional response, cognition.

The association of the neuroprotective factor in the treatment with second generation antipsychotic drugs for schizophrenia with negative symptoms reduces the cognitive deterioration counterpoising the neurotransmitters balances (especially GABA and Glutamate), improving the prognosis of the disorder.